Literature DB >> 29288467

Prognostic factors of regrowth in nonfunctioning pituitary tumors.

Gerald Raverot1,2,3, Alexandre Vasiljevic4,5,6, Emmanuel Jouanneau4,5,7.   

Abstract

Surgery is the treatment of choice for nonfunctioning pituitary tumors (NFPTs). Postoperative tumor regrowth during follow-up is present in about half of the patients with invasive NFPTs with residual tumor but occurs also in 15% of patient without residue. Therapeutic strategies should consider this risk of recurrence and the potential side effects associated with therapeutic options. Identification of prognostic markers is mandatory to help clinicians to predict the risk of recurrence and to choose the best strategy between conservative follow-up, second surgery, postoperative adjuvant radiation therapy, and medical treatment (dopamine agonists, somatostatin analogs). Recent advances in pathological classification may be the first step for identification of NFPTs with a high risk of recurrence.

Entities:  

Keywords:  Gonadotroph tumor; Nonfunctioning pituitary tumor; Pituitary tumor; Prognostic markers; Silent pituitary tumor

Mesh:

Substances:

Year:  2018        PMID: 29288467     DOI: 10.1007/s11102-017-0861-3

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  55 in total

1.  Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma.

Authors:  P Kremer; M Forsting; G Ranaei; C Wüster; J Hamer; K Sartor; S Kunze
Journal:  Acta Neurochir (Wien)       Date:  2002-05       Impact factor: 2.216

Review 2.  Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis.

Authors:  Yong Chen; Cheng De Wang; Zhi Peng Su; Yun Xiang Chen; Lin Cai; Qi Chuan Zhuge; Zhe Bao Wu
Journal:  Neuroendocrinology       Date:  2012-08-28       Impact factor: 4.914

Review 3.  MicroRNAs in pituitary tumors.

Authors:  Anne Wierinckx; Magali Roche; Catherine Legras-Lachuer; Jacqueline Trouillas; Gérald Raverot; Joël Lachuer
Journal:  Mol Cell Endocrinol       Date:  2017-01-13       Impact factor: 4.102

4.  Letter to the editor.

Authors:  Kalman Kovacs; Fabio Rotondo; Eva Horvath; Luis V Syro; Antonio Di Ieva; Michael D Cusimano; David G Munoz
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

5.  Endocan, a new invasion and angiogenesis marker of pituitary adenomas.

Authors:  Fumihiro Matano; Daizo Yoshida; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; Akio Morita
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

6.  Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas.

Authors:  Ali Erdem Yildirim; Denizhan Divanlioglu; Osman Arikan Nacar; Engin Dursun; Mert Sahinoglu; Tuba Unal; Ahmed Deniz Belen
Journal:  Turk Neurosurg       Date:  2013       Impact factor: 1.003

Review 7.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

8.  Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth.

Authors:  Y Greenman; G Ouaknine; I Veshchev; I I Reider-Groswasser; Y Segev; N Stern
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

Review 9.  Clinicopathological prognostic and theranostic markers in pituitary tumors.

Authors:  Alexandre Vasiljevic; Emmanuel Jouanneau; Jacqueline Trouillas; Gérald Raverot
Journal:  Minerva Endocrinol       Date:  2016-03-04       Impact factor: 2.184

Review 10.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

View more
  11 in total

1.  Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification.

Authors:  Marie Buchy; Véronique Lapras; Muriel Rabilloud; Alexandre Vasiljevic; Françoise Borson-Chazot; Emmanuel Jouanneau; Gérald Raverot
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 2.  Diagnosis and treatment of refractory pituitary adenomas: a narrative review.

Authors:  Xiaohai Liu; Congxin Dai; Ming Feng; Mingchu Li; Ge Chen; Renzhi Wang
Journal:  Gland Surg       Date:  2021-04

3.  K i -67/MIB-1 and Recurrence in Pituitary Adenoma.

Authors:  Kent Tadokoro; Colten Wolf; Joseph Toth; Cara Joyce; Meharvan Singh; Anand Germanwala; Chirag Patel
Journal:  J Neurol Surg B Skull Base       Date:  2021-09-21

4.  Gonadotroph Tumors Show Subtype Differences That Might Have Implications for Therapy.

Authors:  Mirela Diana Ilie; Alexandre Vasiljevic; Camille Louvet; Emmanuel Jouanneau; Gérald Raverot
Journal:  Cancers (Basel)       Date:  2020-04-20       Impact factor: 6.639

5.  Presentation, Management, and Outcomes of Nonfunctioning Pituitary Adenomas: An Experience from a Developing Country.

Authors:  Bhagwan Das; Sumera Batool; Adeel Khoja; Najmul Islam
Journal:  Cureus       Date:  2019-09-25

6.  The Search of miRNA Related to Invasive Growth of Nonfunctioning Gonadotropic Pituitary Tumors.

Authors:  Joanna Boresowicz; Paulina Kober; Natalia Rusetska; Maria Maksymowicz; Agnieszka Paziewska; Michalina Dąbrowska; Natalia Zeber-Lubecka; Jacek Kunicki; Wiesław Bonicki; Jerzy Ostrowski; Janusz A Siedlecki; Mateusz Bujko
Journal:  Int J Endocrinol       Date:  2020-12-05       Impact factor: 3.257

7.  Invasive and Noninvasive Nonfunctioning Gonadotroph Pituitary Tumors Differ in DNA Methylation Level of LINE-1 Repetitive Elements.

Authors:  Natalia Rusetska; Paulina Kober; Sylwia Katarzyna Król; Joanna Boresowicz; Maria Maksymowicz; Jacek Kunicki; Wiesław Bonicki; Mateusz Bujko
Journal:  J Clin Med       Date:  2021-02-03       Impact factor: 4.241

8.  Intratumoural spatial distribution of S100B + folliculostellate cells is associated with proliferation and expression of FSH and ERα in gonadotroph tumours.

Authors:  Mirela Diana Ilie; Alexandre Vasiljevic; Marie Chanal; Nicolas Gadot; Laura Chinezu; Emmanuel Jouanneau; Ana Hennino; Gérald Raverot; Philippe Bertolino
Journal:  Acta Neuropathol Commun       Date:  2022-02-09       Impact factor: 7.801

9.  BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.

Authors:  Chengzhang Shi; Zhao Ye; Jie Han; Xiaoqing Ye; Wenchao Lu; Chenxing Ji; Zizhou Li; Zengyi Ma; Qilin Zhang; Yichao Zhang; Wenqiang He; Zhengyuan Chen; Xiaoyun Cao; Xuefei Shou; Xiang Zhou; Yongfei Wang; Zhaoyun Zhang; Yiming Li; Hongying Ye; Min He; Hong Chen; Haixia Cheng; Jun Sun; Jianyong Cai; Chuanxin Huang; Fei Ye; Cheng Luo; Bing Zhou; Hong Ding; Yao Zhao
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

10.  A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years.

Authors:  Yu Zhang; Yuqi Luo; Xin Kong; Tao Wan; Yunling Long; Jun Ma
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.